Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 13/20 | 0.57 |
| ▸ | CDK8 | P49336 | 13/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15742786 | 0.85 | CCNC (0.54) | CCNCCDK8PIM1PARP1 | |
| SCHEMBL15747592 | 0.85 | CCNC (0.54) | CCNCCDK8PIM1CDC7RPS6KA3 | |
| SCHEMBL15742986 | 0.84 | CCNC (0.54) | CCNCCDK8CDC7RPS6KA3PARP1 | |
| SCHEMBL15742747 | 0.84 | CCNC (0.69) | CCNCCDK8PIM1PARP1 | |
| SCHEMBL4580346 | 0.84 | CCNC (0.64) | CCNCCDK8PIM1RPS6KA3PARP1 | |
| SCHEMBL15742848 | 0.83 | CCNC (0.53) | CCNCCDK8PIM1RPS6KA3 | |
| SCHEMBL15747451 | 0.82 | CCNC (0.52) | CCNCCDK8PIM1RPS6KA3 | |
| SCHEMBL1726194 | 0.81 | CCNC (0.51) | CCNCCDK8PIM1PARP1ADORA1 | |
| SCHEMBL15742770 | 0.81 | CCNC (0.51) | CCNCCDK8PIM1 | |
| SCHEMBL15747517 | 0.81 | CCNC (0.56) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | claimed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | CBR3, CBR1, NR2C2 | CCNC 1270/4885CDK8 3289/4885PIM1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.